Professional Documents
Culture Documents
Gastric Cancer
Gastric Cancer
cells (ECLs).
The structure of gastric gland
from fundus or body,
Acid and pepsinogen producing
glands are referred to as
oxyntic glands.
Parietal cells referred as
oxyntic cells.
Chief cell referred as peptic
cell.
Incidence of gastric cancer:
The incidence of gastric cancer in male are two to three times more susceptible
than female.
The incidence is noted that more than 50% of new incidents come up in
developing countries.
Areas with the highest risk for gastric cancer include:
Central and South America, Eastern Europe and East Asia (China and
Japan).
The low- regions include:
risk
Australia and New Zealand, Southern Asia, North and East Africa and
North America.
Adenocarcinomas:
It is developed in the epithelial mucosal cells of the stomach.
Lymphoma:
It is a cancer of the lymphoid tissue in the stomach.
Gastrointestinal stromal tumors (GISTs):
Arsis from a special cell found in the lining of the stomach called interstitial
cells of Cajal (ICCs). These tumors may develop through the digestive tract,
but about 60 to 70 % occur in the stomach.
Leiomyosarcomas:
Tumors of smooth muscle of wall of stomach.
Carcinoid tumors: Typically start in the hormone-producing cells of the
stomach. These tumors usually do not spread to different organs.
B. Lauren’s classification:
This classification is based on how the gastric tissue looks and behaves when
examined under a microscope.
This system is most often used to describe how adenocarcinoma tumors (the
most common type of stomach cancer) look and behave.
Low grade:
High grade:
Important of grading:
Knowing the grade gives the healthcare team an idea of how quickly
the cancer may be growing and how likely it is to spread.
This helps them plan the treatment.
The grade can also help the healthcare team predict how you might
respond to treatment.
Staging of gastric cancer (often called the extent of cancer):
The stomach is made up of different layers of tissues. The stage often
depends on which layer the tumor has grown into.
T1b= Submucosa
T3= Serosa
T4= infiltration
Solid tumor cancers may be given both a clinical and pathologic stage.
Based on the results of exams and tests (imaging) done at the time of
diagnosis.
Doctors often choose a treatment based on the clinical stage.
The clinical stage is shown by a lowercase “c” before the letters TNM.
Pathologic stage:
It is based on the results of tests and exams done when the cancer is found and
what is learned about the cancer during surgery and when looking at the
tissue after it is removed by surgery.
It gives more information about the cancer than the clinical stage.
The pathologic stage is shown by a lowercase “p” before the letters TNM on a
pathology report.
The stage of cancer doesn’t change:
Once a person is told what stage the cancer is, the stage of cancer doesn’t change.
If a stage 2 cancer comes back (recurs) after it is treated, it is still stage 2
cancer that has recurred.
And if the cancer has spread to a distant part of the body after it is treated, it
is still stage 2 cancer but it is metastatic.
This is important because the stage at diagnosis is used to study
survival statistics and treatments for specific stages of cancer.
Restaging:
Restaging helps doctors plan further treatment when cancer comes back
or gets worse after the initial treatment.
Restaging doesn’t mean that a stage 2 cancer changes to a stage 3 cancer.
The stage of a cancer doesn’t change.
But a tumor initially staged as a T2 may be described as a T3 or T4 if
the cancer has grown larger or grown into nearby tissues.
This may be found with further tests after treatment. When restaging is
done, it is shown with a lowercase “r” before the letters TNM on a medical
report.
On examination:
Clinical signs are usually absent, especially in the early stages, however
an epigastric mass may be felt in late-stage disease.
Troisier sign is the presence of a palpable left supraclavicular node (Virchow
node) and is considered a sign of metastatic abdominal malignancy
(typically gastric).
Other signs of metastatic disease include hepatomegaly, ascites, jaundice,
or acanthosis nigricans.
Investigations:
A. Laboratory Tests:
Full blood count and liver function tests.
Serological markers:
B. Imaging:
Urgent upper GI endoscopy, allowing for the direct visualization of any
malignancy present and subsequent multiple biopsies (up to 7) taken.
NICE guidelines recommend referring for an urgent upper GI endoscopy, for any
patients presenting with new-onset dysphagia or aged > 55 years
presenting with weight loss and either upper abdominal pain, reflux, or dyspepsia.
Abdominal CT.
Endoscopic ultrasound.
Biopsies from suspected gastric malignancies should be sent for:
Histology – for classification and grading of any neoplasia present
CLO test – for the presence of H. Pylori
HER2/neu protein expression – this will allow for targeted monoclonal
therapies if present.
Treatment:
A. Surgery.
The aim of surgery is to achieve loco-regional control by removing the tumor
and
its local lymph nodes. The type of operation performed depends on the region
of the malignancy:
Proximal gastric cancers – total gastrectomy
Distal gastric cancers (antrum or pylorus) – subtotal gastrectomy
Patients with early T1a tumors (tumors confined to the muscularis
mucosa) may be offered an Endoscopic Mucosal Resection (EMR).
B. Peri-operative chemotherapy.
3. Palliative Management:
Surgery:
Q. 1
Which of the following vitamin deficiency is found in patients with gastric cancer?
A Vitamin C
B Vitamin B 12
C Vitamin A
D Vitamin D
Definitions: